The Operating Theatre Journal July 2022

More documents

Recommendations

Info

Success stories written by MEDICA – how a small developer team witha prototype in their pocket became one of the biggest exhibitorsAgain, many programme highlights feature start-upsAs one of the world’s leading medical trade fairs, MEDICA in Düsseldorf isone of the most important platforms for start-up teams seeking to enterthe healthcare industry and who are looking for investors, opportunities forcooperation and also first-time users of their product ideas. From November14 to 17, 2022, for the duration of MEDICA, numerous programme highlightswill again offer young entrepreneurs the perfect opportunity to presentthemselves to international experts from the healthcare sector: the 11thMEDICA Start-up COMPETITION, 14th Healthcare Innovation World Cup, theMEDICA START-UP PARK and a total of over 100 start-up exhibitions at theMEDICA CONNECTED HEALTHCARE FORUM are just an example.In addition, several hundred start-ups or scale-ups (which have entered thenext phase of development) will participate as exhibitors at MEDICA 2022,either with joint stands or with a stand of their own. The current trend inregistrations for exhibitors points towards a participation rate that exceedsthat of the previous year (MEDICA 2021: 3033 participants) with a notableexpansion in the booked floor capacity.Young companies like Rapid Response Revival are responsible for thisincrease in booked floor capacity. In 2018, they participated for the firsttime, at the central meeting point for start-ups, MEDICA START-UP PARK.Since then, their business has grown exponentially. Thus, Rapid ResponseRevival is travelling from Australia to MEDICA this year, too, and will occupyone of the largest stands.The team of developers has committed themselves and their product tomeet a global challenge; sudden cardiac arrest. Every year, six millionpeople worldwide die of this condition. This often happens at home, whereno life-saving defibrillator is present in time.Therefore, Rapid Response Revival developed “CellAED”, an inexpensivedefibrillator for use by lay persons, and started marketing it. In 2019,the first prototype was exhibited at MEDICA: “We met many people whorecognised our potential and wanted to be part of our endeavour indifferent parts of the world”, Luke Starr, Chief Communications Officer atRapid Response Revival, remembers the promising start-up phase. Much hashappened since then. “We will be presenting a matured product at MEDICA2022”, says Starr, looking forward to the trade fair which will take place inmid-November.As compact as a bar of chocolate, with huge potentialThe new version of the defibrillator is no bigger than a bar of chocolate,connects to a network and shows that it is ready for action. “CellAED”helps first responders save lives until professional aid arrives. The device isintended for integration into various emergency alert systems, and accordingto Starr, could dramatically change first aid response globally. More than 70countries have already issued a certification. The device has been approvedfor the market in the EEA, the UK, Australia and New Zealand.The device should remain affordable wherever it is sold: “The device costsaround 240 Euro. A subscription of approximately ten Euros each monthis also required for ongoing support, which for example includes accessto diagnostic data”, says Starr. CellAED is one-tenth the price, size andweight of many of the other current systems on the market, which makesthe defibrillator perfect for home use. “This device will change society’sreaction to sudden cardiac arrest in a fundamental way”, says Starr.To this end, the upcoming participation in the trade fair is vital: “At MEDICA2022 we will present both our development and the opportunities that itproffers to a professional audience”, says Starr, adding: “We want to sellmillions of devices. We’re therefore cooperating with several manufacturersand are aiming to produce 200,000 devices each month by the end of 2023”.Starr thinks this is realistic: “We have the capacity to meet this challenge,we meet the legal requirements and we have a team that can solve potentialproblems”. One important reason for their success up to now is attributedto the fact that, unlike larger competitors, this company concentrates on asingle application. This experience is probably very similar to that of otherstart-ups which haven’t yet progressed as much as Rapid Response Revivalhas, and which nevertheless have chosen MEDICA as a suitable platform – forexample, because of its competitions.The 11th MEDICA Start-up COMPETITION has kicked offThe 11th MEDICA Start-up COMPETITION is seeking outstanding healthcaresolutions from start-ups in the health app, laboratory diagnostics andartificial intelligence (AI) sectors in health care and robotics. The previousyear, the winning team was ‘Phonolyser’ from Finland, with their eponymousproduct solution that offers intelligent analysis of cardiac sounds. Thecardiac sound analyser combines artificial intelligence (processing andanalysing signals), Doppler technology (ultrasound) and sound analysis tocomprehensively assess and examine for the presence of congenital heartdefects in children. The system aids in exact diagnosis. Bahman Doaeian,co-founder and Chief Business Officer of Phonolyser, says: “Particularly inthe first weeks following our victory in Düsseldorf, we received a lot ofattention from the media and from investors in Europe”.For Doaeian, MEDICA is one of the best platforms on which to introducemedical technology in the world. “Here, we meet exactly the target groupwe want to reach”, he says. Since last November, the “Phonolyser” hasbeen developed further; specifically, sensitivity has been improved (goal:over 98 %) and the software has been optimised to make it easier for lessexperienced doctors to operate the device. Clinical studies have seen alot of progress – for example, for testing a new algorithm. In this context,Doaeian sees the extensive legal requirements for in the European Unionas a challenge that means that more support is needed for start-ups inparticular.Applications for the 11th MEDICA Start-up COMPETITION can be submitted upuntil September 21, 2022. The finals for the winning pitch will be held on theNovember 15 on the event stage at the MEDICA CONNECTED HEALTHCAREFORUM. Information on the competition and registration is available onlineat: https://www.medica-tradefair.com/mac2.The 14th Healthcare Innovation World Cup for “Internet of MedicalThings” solutionsStart-ups, scale-ups and small and medium businesses are also free tosubmit their solutions for the “Internet of Medical Things (IoMT)” to the 14thHealthcare Innovation World Cup. The best 12 selected finalists will be invitedto present their products – which can range from wearable technologies todigital biomarkers, intelligent plasters and smart implants – at MEDICA 2022.In 2021, the “eyemate” system by the Implandata Ophthalmic Productscompany won the finals in Düsseldorf. This is an intelligent, implantable andbiocompatible micro sensor that provides telemedical care for glaucomapatients. Glaucoma patients experience elevated intraocular pressure cancause irreversible damage to the optic nerve and lead to blindness. Currentmethods only allow this to be measured at an ophthalmologist’s office.However, “eyemate” enables patients to continuously monitor themselvesat home. Ophthalmologists can use telemedicine to monitor the dataand, if necessary, intervene early on. The device gives patients a feelingof security, as they will be informed in time and can act before elevatedintraocular pressure can damage their optical nerve. For Max Ostermeier,CEO & Founder of Implandata Ophthalmic Products, this is a form of patientempowerment, which also contributes to adherence to therapy: “Thiswill completely transform glaucoma therapy”. Ostermeier also states thatwinning at the competition at MEDICA was a huge award and was importantfor motivation. He says the media response led to being invited to morepresentations, which made it easier to win over investors.Step by step towards international successNevertheless, the following still remains true for this start-up: “Thedominant factor is still the cost”, says Ostermeier. The implant is currentlybeing piggyback implanted in the eye during operations for glaucomaor cataracts, where it remains indefinitely. “We meet the exacting CEdemands for permanent implants”, says Ostermeier. In the future, theimplant should be able to be implanted via minimally invasive injection,without surgery, so that intraocular pressure can be monitored continuallyduring the early stages of the disease. Ostermeier went on to state that thestart-up works closely with ophthalmologists. In one or two years at theearliest, the company will strive for further internationalisation – outsideGerman-speaking countries. The current focus: approval by the US Food andDrug Administration (FDA).The application phase for participation in this year’s Healthcare InnovationWorld Cup ends on September 21, 2022. The pitches of the 12 finalists willalso take place on the event stage at the MEDICA CONNECTED HEALTHCAREFORUM (on November 14).The MEDICA START-UP PARK (Hall 12, E53), which has established itself as acentral venue for the creative founder scene, also prioritises networking. Atleast 40 start-ups have already announced that they will participate, mostof them focusing on innovative digital healthcare solutions.All information on MEDICA 2022 and the parts of the programme mentionedabove is available online at: https://www.medica-tradefair.com.Author: Dr Lutz Retzlaff, freelance medical journalist (Neuss)20 THE OPERATING THEATRE JOURNAL www.otjonline.com
THESEPTEMBER 2020 ISSUE NO. 360 ISSN 0000-000XTHETHEOTJONLINE.COMSEPTEMBER 2020 ISSUE NO. 360 ISSN 0000-000XThe Operating SEPTEMBER 2020 ISSUE NO. Theatre 360 ISSN 0000-000XJournalThe TheOperating OperatingTheatre WWW.OTJONLINE.COMTheatreJournalGet Your Personal copy fromThe Leading Independent Print & Digital Journal For ALL Operating Theatre StaffODPs, Theatre, Anaesthetic & Recovery NursesYour Favourite Journal is available ONLINEOTJONLINE.COMOTJONLINE.COMThe Leading Independent Print & Digital Journal For ALL Operating Theatre StaffThe Leading Independent Print & Digital Journal For ALL Operating Theatre StaffJobs, News, Study Days, Books,Clinical Articles £2.00Register Today at:www.otjonline.com£2.00£2.00Jobsite:www.operatingtheatrejobs.comView the journal online @ www.otjonline.comOTJ Back issues are also available to viewnightentify’s newwill aationsbringrsonalto tellnchedtool,et thehcaretivelyumberge ofare, itt is soo thats whorationrightcare,inuityill beentifyProfessor Helen Stokes-Lampard, Chair of the Royal College GPs, said:“Sepsis ACTION is a huge REQUIRED worry for GPs - Calling as initial all symptoms those can involved be similarto in other Cataract common illnesses, Surgery and the - 1 College tree is will putting be a planted lot of effortinto helping family doctors recognise potential sepsis and ensure thatpatients rapidly for every receive appropriate 100 completed assessment and surveys treatment.UK Attitudes towards waste in Cataract Surgery“We have produced a toolkit, in partnership with NHS England, whichbrings together existing guidance, training materials and patientinformation Cataracts remain to encourage the leading us all to cause ‘think of sepsis, blindness talk sepsis worldwide, and treat andsepsis’. cataract surgery is the most commonly performed surgical procedurein the UK, and worldwide.“We are pleased to be working with NHS England to raise awarenessandOneimprovecataractoutcomesoperationforinpatients.the UKItgeneratesreally couldthesaveCO2lives.”equivalentemissions as driving a car 310 miles. Conversely, the Arvind Eye CareAnna System Crossley, in India generates Professional the Lead equivalent for Acute, CO2 emissions Emergency of driving & Critical justCare 16 miles, at the with RCN, comparable, said: “Sepsis if not is a better life-threatening clinical outcomes. condition and earlyidentication is the key to survival, but it can be difcult to diagnoseWhy is our carbon footprint per case higher than other nations? Whatand often symptoms can be mistaken for a u-like illness. This is whyare the perceived barriers to reducing our carbon footprint?raising awareness among carers, health care professionals and thepublic We need is so to vital. know Even your though views there to help has been quantify good and progress thus to tackle improve thediagnosis, problem, so a cohesive please spare national just plan 10 minutes is needed of your to ensure time to that complete healthcare theprofessionals survey; https://www.cvent.com/d/fjq161/3Bare supported and equipped to identify and treat sepsisearly.For every 100 completed surveys, 1 tree will be planted, by NHS forests“If https://nhsforest.org/sponsor-treesepsis is not recognised quickly, it can lead to shock, multiple organfailure This project and death, is dependent which is on why your early support. detection The is survey critical itself to start wastreatment developed within in collaboration the hour. with Nurses Professor and health Chang care and support Thiel in workers, the USwho see have their published patients their on survey a regular results basis, and and subsequent are often work. the rst Thehealthcare survey asks worker for emails to see and them, names are but well it is placed completely to recognise anonymous. the signs Theof names sepsis and early emails and are raise kept the to alarm. prevent If duplicate a person has responses, signs or and symptoms for youthat to come indicate back possible to the survey infection, should think you get ‘could pulled this away. be sepsis?’ and actfast to raise the alarm, wherever you are.Thank you in advance for your engagement in the mission to achievehttps://www.england.nhs.uk/wp-content/uploads/2015/08/Sepsis-carbon neutrality in the NHS by 2030!Action-Plan-23.12.15-v1.pdfEllie McCance, W.I.S.E Sustainability Scholar in Ophthalmologytwitter.com/OTJOnlineRegistration is Free !www.otjonline.comCentral Medical Supplies AppointedUK Distributor For TrueCool PremiumCentral Medical Supplies (CMS) has been appointed as the exclusiveUK distributor for TrueCool Premium. Manufactured by EM-MED,TrueCool Premium is a device used to carry out targeted temperaturemanagement.TrueCool is used to reduce thecore body temperature in patientswho do not regain consciousnessafter the return of spontaneouscirculation following a cardiacarrest. The device then maintainsthe temperature for 24 hoursbefore slowly rewarming.TrueCool Premium comes with ahigh accuracy temperature sensor(0.05°C), along with the ability toadjust the temperature in steps of0.05°C. The device has a userfriendly 10 inch touch screenand a database for off-lineanalysis and data export.A wide range of patientcovers is available with thesystem. There is also a UVdisinfection option, to minimisecleaning time.Tracey Pavier-Grant, Sales & Marketing Director at Central MedicalSupplies, says: “TrueCool Premium is a great addition to our temperaturemanagement portfolio. We’re looking forward to demonstrating thebenefits of TrueCool to healthcare professionals and discussing theimportant role of fast patient cooling in certain cardiac treatments.”For more information on TrueCool Premium, contact Tracey Pavier-Grant, Sales & Marketing Director at Central Medical Supplies, on 01538392 596 or email tracey@centralmedical.co.uk. Further details are alsoavailable by visiting the CMS website at:www.centralmedical.co.ukWhen responding to articles please quote ‘OTJ’wrand.com Issue 316 January 2017 7Find out more 02921 680068 • e-mail admin@lawrand.com Issue 382 July 2022 21
Page 1 and 2: THE THETHESEPTEMBER JULY 2020 2022
Page 3 and 4: THE THETHESEPTEMBER JULY 2020 2022
Page 5 and 6: Operating Department Practitioner -
Page 7 and 8: Full Conference: £95One Day: £60w
Page 9 and 10: #StepForwardURGENTLYSEEKING:Consult
Page 11 and 12: Table Five Five - NHS England - NHS
Page 13 and 14: Jointoday from£6*AfPP has helped m
Page 15 and 16: New report reveals underestimated r
Page 17 and 18: Thank you for reading, the extended
Page 19: The Association for Perioperative P
Page 23 and 24: www.OperatinggTheatreJobs.comA one-
Page 25 and 26: Becoming an NHS Forest tree sponsor
Page 27 and 28: The Operating Theatre JournalDiscov
Page 29 and 30: Unisurge keeps sight of surgical su
Page 31 and 32: Clinical Update Advantages and Upgr

The Operating Theatre Journal July 2022

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?